# Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome

> **NCT03501459** · PHASE3 · UNKNOWN · sponsor: **National University Health System, Singapore** · enrollment: 100 (estimated)

## Conditions studied

- Nephrotic Syndrome

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03501459
- **Lead sponsor:** National University Health System, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-06
- **Primary completion:** 2020-12
- **Final completion:** 2025-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03501459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03501459, "Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03501459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*